

Diagnosis and Management of *Mixed-Phenotype ATTR*

Monday, Dec 1st, 2025

7:30 – 9:00 pm EST

Best Practices Forum: Diagnosis and Management of Mixed-Phenotype ATTR

This case-based virtual program will provide an evidence-based review of the prevalence, diagnosis, and management of mixed-phenotype ATTR amyloidosis (ATTRv), including new Canadian consensus recommendations and current therapeutic options.

Session Objectives

- Examine the prevalence, diagnosis, and management of mixed-phenotype ATTR amyloidosis (ATTRv), alongside newly published Canadian consensus recommendations
- Discuss the significance of a multidisciplinary approach to managing ATTRv, involving collaboration between neurology, cardiology and primary care
- Review current and emerging therapeutic options for ATTRv

Faculty



Milan Gupta – Chair
MD, FRCPC, FCCS, CPC(HC)

Assistant Professor, Department of Medicine,
University of Toronto
Medical Director,
Collaborative CME and Research Network
Brampton, ON



Nowell Fine
MD, SM, FRCPC

Clinical Assistant Professor of Cardiac Sciences,
Cumming School of Medicine,
University of Calgary
Calgary, AB



Ahmad Masri
MD, MS

Associate Professor of Medicine,
Division of Cardiovascular Medicine,
OHSU School of Medicine
Portland, OR



Genevieve Matte
MDCM, FRCPC

Assistant Professor,
Department of Neurosciences,
University of Montreal
Montreal, QC



Register at:
www.ccrnmd.com

For program inquiries, contact:
info@ccrnm.com



This program was developed by the Collaborative CME and Research Network and has received an educational grant from AstraZeneca.